BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 18000086)

  • 1. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
    Chan DC; Nguyen MN; Watts GF; Barrett PH
    J Clin Endocrinol Metab; 2008 Feb; 93(2):557-64. PubMed ID: 18000086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men.
    Chan DC; Barrett PH; Ooi EM; Ji J; Chan DT; Watts GF
    J Clin Endocrinol Metab; 2009 Mar; 94(3):989-97. PubMed ID: 19116237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins.
    Le NA; Gibson JC; Ginsberg HN
    J Lipid Res; 1988 May; 29(5):669-77. PubMed ID: 3411241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.
    Ooi EM; Chan DT; Watts GF; Chan DC; Ng TW; Dogra GK; Irish AB; Barrett PH
    J Lipid Res; 2011 Apr; 52(4):794-800. PubMed ID: 21297177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
    Chan DC; Watts GF; Redgrave TG; Mori TA; Barrett PH
    Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III.
    Ooi EM; Chan DC; Hodson L; Adiels M; Boren J; Karpe F; Fielding BA; Watts GF; Barrett PH
    Eur J Clin Invest; 2016 Aug; 46(8):730-6. PubMed ID: 27378472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
    Chan DC; Watts GF; Nguyen MN; Barrett PH
    Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):590-6. PubMed ID: 16410456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome.
    Ooi EM; Watts GF; Chan DC; Chen MM; Nestel PJ; Sviridov D; Barrett PH
    Diabetes Care; 2008 Aug; 31(8):1656-61. PubMed ID: 18509206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein A-II and adiponectin as determinants of very low-density lipoprotein apolipoprotein B-100 metabolism in nonobese men.
    Chan DC; Watts GF; Ooi EM; Chan DT; Wong AT; Barrett PH
    Metabolism; 2011 Oct; 60(10):1482-7. PubMed ID: 21550083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.
    Chan DC; Wong AT; Pang J; Barrett PH; Watts GF
    Clin Sci (Lond); 2015 Mar; 128(6):379-85. PubMed ID: 25291660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
    Chan DC; Watts GF; Ooi EM; Ji J; Johnson AG; Barrett PH
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1831-7. PubMed ID: 18566295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
    Batal R; Tremblay M; Barrett PH; Jacques H; Fredenrich A; Mamer O; Davignon J; Cohn JS
    J Lipid Res; 2000 May; 41(5):706-18. PubMed ID: 10787431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.
    Cohn JS; Patterson BW; Uffelman KD; Davignon J; Steiner G
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3949-55. PubMed ID: 15292332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux.
    Chan DC; Hoang A; Barrett PH; Wong AT; Nestel PJ; Sviridov D; Watts GF
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1658-66. PubMed ID: 22745238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice.
    Weinstock PH; Bisgaier CL; Hayek T; Aalto-Setala K; Sehayek E; Wu L; Sheiffele P; Merkel M; Essenburg AD; Breslow JL
    J Lipid Res; 1997 Sep; 38(9):1782-94. PubMed ID: 9323588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome.
    Batista MC; Welty FK; Diffenderfer MR; Sarnak MJ; Schaefer EJ; Lamon-Fava S; Asztalos BF; Dolnikowski GG; Brousseau ME; Marsh JB
    Metabolism; 2004 Oct; 53(10):1255-61. PubMed ID: 15375779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III.
    Chan DT; Dogra GK; Irish AB; Ooi EM; Barrett PH; Chan DC; Watts GF
    J Lipid Res; 2009 Dec; 50(12):2524-31. PubMed ID: 19542564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.